

## Original Research Article

### Tigecycline resistance, a clinical challenge: Experience from a tertiary care center of North India

#### ABSTRACT

**Introduction:** Tigecycline is a unique tetracycline class of semi-synthetic, last-line broad spectrum antibiotic against multi-drug-resistant bacteria. However, recently, resistance to this antibiotic is on the rise.

**Aims:** This study was conducted to determine the prevalence of tigecycline resistance amongst carbapenem-resistant Gram-negative bacilli (GNB) isolated from clinical samples (pus and sputum) as well as to evaluate their antimicrobial susceptibility pattern.

**Study design:** Prospective cross sectional

**Place and Duration of Study:** Department of Microbiology at Sanjay Gandhi Post Graduate Institute of Medical Sciences Lucknow, between January 2023 and December 2023.

**Methodology:** Identification of GNB grown on culture was done by conventional biochemical tests and later validated by MALDI-TOF MS. The antimicrobial sensitivity testing of isolates was done using the E-test, and disk diffusion method. Minimum inhibitory concentration determination was done by Broth micro-dilution (BMD) method.

**Results:** Amongst 8326 pus and respiratory samples, GNBs were recovered from 63.15% (5258/8326). Of 5258 GNB isolates, 50.74% (2668) were carbapenem-resistant, while 7.85% (413) demonstrated resistance to both tigecycline and carbapenem. Common isolates in this group were *Klebsiella pneumoniae* (37.04%), *Acinetobacter* spp. (25.18%), *Enterobacter* spp. (14.28%) and *Escherichia coli* (12.59%). BMD results demonstrated highest activity of tigecycline against carbapenem-resistant *E. coli*, followed by *Citrobacter* and *Enterobacter*. It works against resistant strains of *Acinetobacter baumannii* and *K. pneumoniae* as well, but in higher concentrations.

**Conclusion:** Increasing tigecycline resistance (one of the last-resort drugs) among carbapenem resistant GNB isolates is a matter of clinical concern, leaving physicians with limited options for treatment of such infections. Proper adherence to the policies of antimicrobial stewardship

programs can reduce the emergence of resistance.

*Keywords: Antibiotic, Bacteria, Carbapenem-resistant, Gram-negative, Tigecycline*

## 1. INTRODUCTION

Antibiotics are widely used to fight bacterial infections. They have revolutionized medical treatment in the last century. Introduction of modern day Penicillin by Alexander Fleming in 1928 set up the paradigms for many new group of anti-microbials. [1]. Antibiotics target either the metabolic functions or the growth process of bacteria. Drugs that target the bacterial enzymes, cell wall or cell membrane are bactericidal, while those affecting protein syntheses are bacteriostatic. [2, 3]. Widespread use, easy access and evolutionary processes over a long period have led to rise in drug resistance. Resistant bugs are responsible for life-threatening infections and one of the main reasons for increased mortality among infected patients. [4]. Tetracyclines, which are known for their broad spectrum of activity against a wide range of Gram-positive and Gram-negative pathogens are at times the only agent which demonstrate sensitivity to the causative organism. New derivatives of the antibiotics in this group are capable of thwarting majority of the resistance mechanisms present in bacteria [5]. Tigecycline is a unique tetracycline class of semi-synthetic, broad-spectrum drug used as the last-line treatment option against multi-drug-resistant Gram-positive and Gram-negative bacteria [6]. It was approved by the Food and Drug Administration (FDA) in 2005 for all severe infections, but in 2010, the FDA issued an alert that it can be used only in the treatment of severe infections of complicated skin and skin structure infection (cSSSI), complicated intra-abdominal infection (cIAI), and community-acquired bacterial pneumonia (CAP) [7]. Being an intravenous and bacteriostatic antibiotic; it is always used in combination with drugs like carbapenems, cephalosporins or quinolones [8–10]. Physicians refrain from using this antibiotic for endovascular infections because of its high volume of distribution leading to poor serum concentration [11]. The mechanism of action of tigecycline is alike other tetracycline group of antibiotics. It acts as an inhibitor of bacterial protein elongation via reversible binding to a helical region of 16s rRNA in the 30s subunit of the bacterial ribosome and physically prevents the elongation factor Tu-GTP aminoacyl t-RNA complex from binding to the A-site and decoding mRNA. The binding of this antibiotic prevents the incorporation of amino acid residues into the elongation of the peptide chain and results in the loss of peptide formation and bacterial growth [12, 13].

According to a review, tigecycline resistance rate in Africa from 2004 to 2016 was about 5.8%, which was much lower than that observed in Europe (37.4%) and North America (36.8%) [7]. Significantly high resistance rates against tigecycline was noted in USA: 9.2% in *K. pneumonia*, 20.8% in *Enterobacter aerogenes*, 38.5% in *Klebsiella oxytoca*, 25.4% in *E. cloacae* and 20.0% in *Serratia marcescens* [7]. A study conducted by Sader *et al.* in Europe documented reduced susceptibility to tigecycline among 11.4% of the carbapenem-resistant

Enterobacteriaceae [14]. Between the year 2005 and 2007, seven medical centers in India, documented low susceptibility (70.6%) to tigecycline [15]. In 2019, another study from South India demonstrated low susceptibility to tigecycline among *Klebsiella spp.* (84%) when compared to *E. coli* (98%) and *Enterobacter spp.* (98%). [16]. Tigecycline is an effective antibiotic against multidrug resistant (MDR) - *E. coli* and *K. pneumoniae* having Minimum inhibitory concentration (MIC) - 90 levels of 0.5 µg/ml and 4 µg/ml, respectively [17].

This study was undertaken to determine the prevalence of tigecycline resistance in carbapenem-resistant gram-negative bacteria in clinical samples (pus and sputum) and also to evaluate their antimicrobial susceptibility patterns.

## 2. MATERIAL AND METHODS:

The study was conducted in the Department of Microbiology at Sanjay Gandhi Post Graduate Institute of Medical Sciences Lucknow, a 1600-bed tertiary care hospital, between January 2023 and December 2023. Clinical samples received in the bacteriology lab during the study period were first subjected to direct Gram staining and microscopy, following which, culture on blood agar and MacConkey agar was done and the culture plates were incubated overnight at 37°C. Colonies observed on the culture plates after incubation were processed according to standard laboratory methods that involved Gram staining of the colonies to differentiate between Gram-positive and Gram-negative bacteria. Conventional biochemical tests were used to identify the isolates which were further validated by Matrix-assisted Laser Desorption Ionization Time of Flight Mass Spectrometry (MALDI-TOF-MS) [18]. *Escherichia coli* ATCC strain (ATCC8739) was used as control in MALDI-TOF MS. All biochemical tests were done in our laboratory according to standard protocols [19]. GNBs that were isolated and identified from the non-duplicate pus and respiratory samples were included in our study. *Pseudomonas*, *Proteus*, and *Morganella* species were not considered, as these show intrinsic resistance to tigecycline due to efflux mechanism. Antimicrobial sensitivity testing of all the selected gram-negative isolates was done using the E-test method for tigecycline and colistin, while the Kirby-Bauer disk diffusion method was used for imipenem (10µg), meropenem (30µg), amikacin (30µg), ceftriaxone (30µg), ceftazidime (30µg), cefoperazone + sulbactam, and minocycline (30µg). Breakpoints for tigecycline were interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines [20]. Breakpoints of colistin and zone diameters of other antibiotics were interpreted according to the Clinical and Laboratory Standards Institute (CLSI) 2022 M-100 [21]. The BMD tests were performed for imipenem, meropenem, and tigecycline and minimum inhibitory concentration (MIC) was determined.

### Statistical Analyses

Data were recorded and analyzed by Microsoft Access, and Excel software version 25 of SPSS. Descriptive statistics such as percentage, frequency, and cross-tabulation were used in our study to represent the results in the form of graphs and tables.

**Comment [u1]:** Make sure the font size is uniform throughout the write-up.

Align your text both left and right (Justified text alignment)

### 3. results and discussion:

A total of 8,326 clinical samples (5344 pus/exudate and 2982 respiratory samples including sputum, tracheal aspirate, bronchioalveolar lavage) were received in our bacteriology laboratory at Department of Microbiology in SGPGIMS, Lucknow during the study period, out of which, 63.15% (n=5258/8326) were culture-positive for GNB. On performing the antimicrobial susceptibility testing for all positive cultures, 50.74% (n=2668/5258) were resistant to at least two antibiotics in the carbapenem group; 8.1% (n=426/5258) isolates were resistant to tigecycline; and 7.85% (n=413/5258) were resistant to both carbapenems and tigecycline [Fig. 1].





Figure 1: Antibiogram of Gram-negative bacilli recovered in clinical samples

Among the tigecycline resistant (n=426) isolates, 45.77% (n=195/426) were resistant to colistin, 46% (n=196/426) to minocycline, 93.66% (n=399/426) to beta-lactamase inhibitors, 94.13% (n=401/426) to cephalosporin, 77.46% (n=330/426) to aminoglycosides and 91.78% (n=391/426) to fluoroquinolones [Table.1]. Out of all tigecycline resistant isolates only 13 isolates were carbapenem sensitive.

Antibiotics	Resistant (%)	Sensitive (%)
<b>Colistin</b>	195 (45.77%)	232 (54.23%)
<b>Minocycline</b>	196 (46%)	230 (54%)
<b>BL+BLI</b>	399 (93.66%)	27 (6.34%)
<b>Cephalosporin</b>	401 (94.13%)	25 (5.87%)
<b>Aminoglycosides</b>	330 (77.46%)	343 (22.54%)
<b>Fluoroquinolones</b>	391 (91.78%)	35 (8.22%)

Table 1: Representation of other antibiotic resistance in isolates resistant to tigecycline (n=426)

Out of the 413 tigecycline and carbapenem-resistant isolates, 37.04% (n=153/413) were identified as *Klebsiella pneumoniae*, 25.18% (n=104/413) as *Acinetobacter baumannii*, 14.28% (n=59/413) as *Enterobacter spp.*, 12.59% (n=52/413) as *Escherichia coli*, 9.68% (n=40/413) as *Citrobacter species*, and 1.21% (n=5/413) as *Klebsiella oxytoca*. [Fig.2]



**Figure 2: Identification of bacterial isolates which were resistant to both tigecycline and carbapenem (n=413)**

Among the isolates resistant to both carbapenem and tigecycline (n = 413), majority 70.9% (n=292/413) demonstrated simultaneous resistance towards aminoglycosides, first-generation cephalosporin, fluoroquinolones, and beta-lactamase inhibitors and 4.35% (n=18/413) were resistant to first-generation cephalosporin but were sensitive to fluoroquinolones and aminoglycosides, while 3.2% (n=13/413) isolates were resistant to aminoglycosides but were sensitive to first-generation cephalosporin and fluoroquinolones. The MIC of the clinical strains was determined by the BMD method. Fifty isolates of each strain and 40 isolates of *Citrobacter spp.* (due to less number) were included to determine the MIC value of imipenem, meropenem, and tigecycline [Table 2]. All isolates were resistant to imipenem, meropenem and tigecycline except 2 isolates of *Acinetobacter*, one isolate of *Enterobacter* and two isolates of *E. coli*, which were showing intermediate sensitivity to meropenem. Three isolates of *Enterobacter*, two of *Citrobacter*, three of *E. coli* were moderately sensitive to tigecycline [Table 2].

Organism/ No. of Isolates	Antibiotics of (range tested in µg/ml)	CLSI/ EUCAST breakpoint ≤S/≥R	Number of isolates with MIC (µg/ml)											% R
			≤1	≤2	4	8	16	32	64	128**	256	512	≥512	
<i>Acinetobacter</i> (50)	Imipenem (1-512)	≤1/≥4	-	-	-	-	6	1	4	4	14	14	7	100
	Meropenem (1-512)	≤1/≥4	-	-	2	1	3	2	2	17	6	8	9	96
	Tigecycline* (1-128)	≤1/≥2	-	-	8	7	3	7	13	(≥)12				100
<i>K. pneumoniae</i> (50)	Imipenem (1-512)	≤1/≥4	-	-	-	2	6	3	7	19	1	7	5	100
	Meropenem (1-512)	≤1/≥4	-	-	-	3	3	2	5	17	9	8	3	100
	Tigecycline* (1-128)	≤1/≥2	-	-	3	9	18	7	6	(≥)7				100

<i>Enterobacter</i> (50)	Imipenem (1-512)	≤1/≥4	-	-	-	4	3	7	11	8	9	3	5	100
	Meropenem (1-512)	≤1/≥4	-	-	1	3	5	9	12	7	6	3	4	98
	Tigecycline* (1-128)	≤1/≥2	-	3	9	17	10	6	3	(≥)2				94%
<i>Citrobacter</i> (40)	Imipenem (1-512)	≤1/≥4	-	-	-	2	6	7	6	4	9	2	4	100
	Meropenem (1-512)	≤1/≥4				3	6	4	11	9	4	2	1	100
	Tigecycline* (1-128)	≤1/≥2	-	2	8	13	4	5	7	(≥)1				95%
<i>E. coli</i> (50)	Imipenem (1-512)	≤1/≥4	-	-	-	3	2	-	3	18	17	5	2	100
	Meropenem (1-512)	≤1/≥4	-	-	2	3	4	4	13	16	5	2	1	96
	Tigecycline* (1-128)	≤1/≥2	-	3	9	17	8	1	6	(≥)6				94%

\* EUCAST guidelines were followed to define breakpoints for Tigecycline, % R (Resistant)

Table 2: MIC distributions for isolates for Imipenem, Meropenem and Tigecycline

Comment [u2]: The title of th Tables are on top while Graph titles are at the bottom. Please move the title caption to the top of the table

## Discussion:

Antimicrobial resistance (AMR) with MDR strain has become a major global health issue [22]. The effectiveness of our current arsenal of antibiotics has been substantially hampered by AMR, and there are high chances that if a new drug is approved for clinical usage, it would eventually follow a similar pattern of development of resistance [23]. Tetracycline groups of antibiotics are widely used in the prevention and treatment of various types of bacterial infections (respiratory, skin, genital etc.) [24]. A new class of glycylycine called tigecycline, has a broader spectrum of antibiotic activity that can inhibit both Gram-positive and Gram-negative bacteria as well as atypical, anaerobic, and antibiotic-resistant [microbes organisms](#) [25]. The Tigecycline Evaluation and Surveillance Trial (TEST) study, which was undertaken globally between 2004 and 2014 to monitor the *in vitro* activities of tigecycline and a panel of antimicrobials against a range of clinically significant pathogens, described the effectiveness of tigecycline against MDR Gram-negative organisms like *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and members of the *Enterobacteriaceae*. It was observed that 13% (n= 21,967/170,759) of isolates were MDR with maximum resistance observed among *Acinetobacter baumannii* isolates (44%). Low rates of tigecycline resistance among *Enterobacteriaceae* i.e. 15% (n=357/2402) for *Enterobacter* spp., 6% (n=235/4098) for *Klebsiella* spp. and 0.2% (n=8/3,222) for *E. coli* was observed in this global study [26]. In the current study, it was found that there was a high rate of carbapenem and tigecycline resistance, among GNB isolates. Another striking finding in this study was that amongst the isolates that were resistant to both tigecycline and carbapenems (n = 413), simultaneous resistance to beta-lactam-beta-lactamase inhibitors (BL-BLI) (93.66%), colistin (45.77%), minocycline (46%), cephalosporin (94.13%), aminoglycosides (77.46%), and fluoroquinolones (91.78%) was evident. After extensive search of the literature, to the best of our knowledge, this is the first time that resistance to other antibiotics in tigecycline and carbapenem-resistant isolates has been reported from India. However, concurrent resistance to carbapenems, aminoglycosides, polymyxins and tigecycline (CAPT-resistant), are increasingly being reported worldwide (Pan drug resistant GNBs in 25 countries in 5 continents) [27]. This indicates that we are already approaching post-antibiotic era. A similar study from a tertiary care hospital in South Korea to evaluate tigecycline resistance in carbapenem-resistant *K pneumoniae* (CRKP) isolates showed resistance rate of 37.8% (17/45) [28] which was higher

than that reported in a multi-centric study done in the United States (18%) [29]. Yan WJ, *et al* in his study from China on Carbapenem-resistant *Enterobacteriaceae* (CRE) showed an overall, 97% (295/305) susceptibility of his isolates to tigecycline and emphasized on improving strategies to monitor the resistant strains [30]. In our study, an increased prevalence of tigecycline resistance (7.85%) among carbapenem-resistant clinical isolates was observed. It was worthy to note that only about 50% of tigecycline-resistant isolates were susceptible to colistin and/or minocycline. Reduced rate of colistin susceptibility in isolates might be due its widespread use in healthcare sectors. Patients referred to tertiary care centres are uniquely threatened by MDR bugs as they have history of being subjected to multiple antibiotic course in the past. Despite being a single center study, the prevalence data from our center includes more than 5000 culture positive isolates. It represents the resistance pattern of a large region in Northern India.

Often the antibiotics available to treat MDR GNB infections are tigecycline and colistin. Widespread use in clinical settings, either as a monotherapy or in combination with other antibiotics, resistance to tigecycline against *Klebsiella* spp. or other *Enterobacteriaceae* is on the rise. [31]. The urgent need for developing more efficient antimicrobial treatments for CRKP infections is highlighted by the recent appearance of CRKP clinical isolates that are resistant to both tigecycline and colistin, as well as by the discovery of a plasmid-mediated colistin resistance gene called MCR-1 [32]. Similar to other studies from different geographical regions, the present study also confirms the emergence of pan-drug and multi-drug-resistant bacteria against last-resort antibiotics [33, 34]. A study from Egypt detected resistance rate of 16.8% of their enterobacterial isolates to both colistin and carbapenems. [35]The evolution of such multidrug-resistant isolates indicates a grim situation shortly where the treatment options for infectious diseases will either be limited or exhausted.

Development of a new class of antibiotic takes almost two to three decades. With the development of resistance against the last [resort](#) antibiotics like colistin and tigecycline, physicians are left clueless in terms of treatment of infectious diseases in the future. It has been speculated that by 2050, antimicrobial drug resistance will kill more people than cancer. There is a need for consolidated and rigorous efforts towards combating the menace of multi- or pan-drug resistance in bacteria to save mankind from infectious diseases.

#### 4. CONCLUSION

Carbapenems are considered one of the best antibiotics for treating infections caused by GNBs, but with the rapid emergence and dissemination of its resistance, physicians are left with limited options i.e. colistin and tigecycline. Knowledge of the local epidemiology and resistance pattern among clinical isolates of our geographical region are mandatory to set strategies of therapy in tertiary care hospitals. As tigecycline is a potential reserve drug, proper adherence to the policies of antimicrobial stewardship programs can reduce the emergence of its resistance. Further research can be done by genomic fingerprinting of the MDR isolates. Also, the in-vitro and in-vivo efficacy of various drug combinations by checkerboard assays and animal model systems can be done.

## CONSENT (WHEREEVER APPLICABLE)

This is a laboratory-based study. Waiver of consent was asked for.

## ETHICAL APPROVAL (WHEREEVER APPLICABLE)

## REFERENCES

1. Aminov RI. A brief history of the antibiotic era: lessons learned and challenges for the future. *Front Microbiol.* 2010 Dec 8;1:134
2. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. *Nat Med.* 2004;10(12 Suppl):S122-S129.
3. Aminov RI. A brief history of the antibiotic era: lessons learned and challenges for the future. *Front Microbiol.* 2010;1:134. Published 2010 Dec 8.
4. Bassetti M, Righi E. Multidrug-resistant bacteria: what is the threat?. *Hematology Am Soc Hematol Educ Program.* 2013;2013:428-432.
5. Grossman TH. Tetracycline Antibiotics and Resistance. *Cold Spring Harb Perspect Med.* 2016;6(4):a025387. Published 2016 Apr 1.
6. Greer, N.D., Tigecycline (Tygacil): the first in the glycylicycline class of antibiotics. *Proc (Bayl Univ Med Cent),* 2006. 19(2): p. 155-61.
7. Yaghoubi S, Zekiy AO, Krutova M, Gholami M, Kouhsari E, Sholeh M, Ghafouri Z, Maleki F. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. *Eur J Clin Microbiol Infect Dis.* 2022 Jul;41(7):1003-1022.
8. Michail, G., et al., Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model. *Antimicrob Agents Chemother,* 2013. 57(12): p. 6028-33.
9. Michail, G., et al., Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model. *Antimicrob Agents Chemother,* 2013. 57(12): p. 6028-33.
10. Petersen, P.J., et al., In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by checkerboard and time-kill kinetic analysis. *Journal of Antimicrobial Chemotherapy,* 2006. 57(3): p. 573-576.
11. Murali dharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. *Antimicrob Agents Chemother.* 2005;49(1):220-229.
12. Linkevičius, M. 2015. Evolution and Mechanisms of Tigecycline Resistance in *Escherichia coli*. *Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine* 1121. 58 pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91- 554-9285-4.

13. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. *Microbiol Mol Biol Rev.* 2001;65(2):232-260.
14. Sader, H.S., et al., Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. *Int J Antimicrob Agents*, 2014. 43(4): p. 328-34.
15. Manoharan, A., et al., Evaluation of tigecycline activity in clinical isolates among Indian medical centers. *Indian J Pathol Microbiol*, 2010. 53(4): p. 734-7.
16. Veeraraghavan B, Poojary A, Shankar C, Bari AK, Kukreja S, Thukkaram B, et al. In-vitro activity of tigecycline and comparator agents against common pathogens: Indian experience. *J Infect Dev Ctries* [Internet]. 2019;13(3):245–50.
17. DiPersio, J.R. and M.J. Dowzicky, Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycolcycline antimicrobial. *Int J Antimicrob Agents*, 2007. 29(5): p. 518-27.
18. Mortier, T., et al., Bacterial species identification using MALDI-TOF mass spectrometry and machine learning techniques: A large-scale benchmarking study. *Computational and Structural Biotechnology Journal*, 2021. 19: p. 6157-6168.
19. Collee, J. G., A. G. Fraser, B. P. Marmion, and A. Simmons. "Mackie and McCartney- Practical Medical Microbiology. Ch. 4." 2007; 53-94.
20. European Committee on Antimicrobial Susceptibility Testing. EUCAST clinical breakpoints. Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases. 2022.
21. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 32 nd ed. CLSI supplement M 100 Clinical and Laboratory Standards Institute; 2022
22. Linkevičius M. Evolution and Mechanisms of Tigecycline Resistance in Escherichia coli. In: Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine. Uppsala; 2015.
23. Pfaller MA, Huband MD, Streit JM, Flamm RK, Sader HS. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016). *Int J Antimicrob Agents*. 2018 Jun;51(6):848-853. doi: 10.1016/j.ijantimicag.2018.01.006.
24. Dean CR, De Pascale G. Resistance of Gram-negative Bacilli to Antimicrobials. In: Fong I, Shlaes D, Drlica K, editors. *Antimicrobial Resistance in the 21st Century Emerging Infectious Diseases of the 21st Century*. Cham: Springer; 2018.
25. Yaghoubi S, Zekiy AO, Krutova M, et al. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. *Eur J Clin Microbiol Infect Dis*. 2022;41(7):1003-1022.

26. Giammanco A, Calà C, Fasciana T, Dowzicky MJ. Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline Evaluation and Surveillance Trial. *mSphere*. 2017;2(1):e00310-16.
27. Karakonstantis S, Kritsotakis EI, Gikas A. Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options. *J Antimicrob Chemother*. 2019;75:271–282.
28. Park Y, Choi Q, Kwon GC, Koo SH. Molecular epidemiology and mechanisms of tigecycline resistance in carbapenem-resistant *Klebsiella pneumoniae* isolates. *J Clin Lab Anal*. 2020;34(12):e23506
29. van Duin D, Cober E, Richter SS, et al. Residence in skilled nursing facilities is associated with tigecycline nonsusceptibility in carbapenem-resistant *Klebsiella pneumoniae*. *Infect Control Hosp Epidemiol*. 2015;36(8):942-948.
30. Yan WJ, Jing N, Wang SM, et al. Molecular characterization of carbapenem-resistant *Enterobacteriaceae* and emergence of tigecycline non-susceptible strains in the Henan province in China: a multicentre study. *J Med Microbiol*. 2021;70(3):001325.
31. Giammanco A, Calà C, Fasciana T, Dowzicky MJ. Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline Evaluation and Surveillance Trial. *mSphere*. 2017 Jan 18;2(1):e00310-16
32. Chen HL, Jiang Y, Li MM, Sun Y, Cao JM, Zhou C, Zhang XX, Qu Y, Zhou TL. Acquisition of Tigecycline Resistance by Carbapenem-Resistant *Klebsiella pneumoniae* Confers Collateral Hypersensitivity to Aminoglycosides. *Front Microbiol*. 2021 Jul 2;12:674502.
33. Elnasser Z, Elsamameh R, Obeidat H, Amarin Z, Jaradat S, Kaplan N. In-vitro activity of tigecycline against multidrug-resistant Gram-negative bacteria: The experience of a university hospital. *J Infect Public Health*. 2021 Apr;14(4):478-483.
34. Osei Sekyere J, Govinden U, Bester LA, Essack SY. Colistin and tigecycline resistance in carbapenemase-producing Gram-negative bacteria: emerging resistance mechanisms and detection methods. *J Appl Microbiol*. 2016 Sep;121(3):601-17.
35. El-Mahallawy HA, El Swify M, Abdul Hak A, Zafer MM. Increasing trends of colistin resistance in patients at high-risk of carbapenem-resistant *Enterobacteriaceae*. *Ann Med*. 2022;54(1):1-9.